Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS)
Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS) - PATIENT
The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics.
LUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages.
LUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging/telehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Indy Li, MS
- Número de telefone: 801-213-5697
- E-mail: indy.li@hci.utah.edu
Locais de estudo
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- Huntsman Cancer Institute/ University of Utah
-
Contato:
- Indy Li, MS
- Número de telefone: 801-213-5697
- E-mail: indy.li@hci.utah.edu
-
Investigador principal:
- Chelsey Schlechter, MPH, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Current or former, male and female, smokers.
- Age 50-80.
- Primary language English or Spanish.
- Have a phone that can send/receive text messages.
Exclusion Criteria:
- Patients who have never smoked.
- Patients who are under the age of 50 or above the age of 80.
- Primary language other than English or Spanish.
- Do not have access to a phone that can send/receive text messages.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Stage 1: TM+
Basic text messages sent directly to the patient's cell phone.
|
Basic text messages sent directly to the patient's cell phone.
|
|
Outro: Stage 1: TM+, CA
Basic text messages sent directly to the patient's cell phone.
Also includes the option for chat bot to answer frequently asked LCS questions.
|
Basic text messages sent directly to the patient's cell phone.
Chat bot to answer frequently asked LCS questions.
|
|
Outro: Stage 1: TM+, Video
Basic text messages sent directly to the patient's cell phone.
Also includes the option for an educational video about LCS.
|
Basic text messages sent directly to the patient's cell phone.
Educational video about LCS.
|
|
Outro: Stage 1: TM+, CA, Video
Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions and option for educational video about LCS. Patients who complete SDM and are referred to LCS will also be assigned to one of the following conditions. Descriptions of these conditions are as follows: |
Basic text messages sent directly to the patient's cell phone.
Chat bot to answer frequently asked LCS questions.
Educational video about LCS.
|
|
Outro: Stage 2: TM+, RPN
Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and reactive patient navigation to help get to the LCS appointment. |
Basic text messages sent directly to the patient's cell phone.
Reactive patient navigation to help get to the LCS appointment.
|
|
Outro: Stage 2:TM+, PPN
Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and proactive patient navigation to help get to the LCS appointment. Patients who need transportation financial assistance will receive transportation vouchers to help get them to and from their LCS appointment. |
Basic text messages sent directly to the patient's cell phone.
Proactive patient navigation to help get to the LCS appointment.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening
Prazo: up to 15 weeks after study enrollment
|
Evaluate the impact of implementation strategies on Lung Cancer Screening (LCS) eligibility screening.
This outcome measure will report the proportion of participants who complete LCS eligibility screening.
|
up to 15 weeks after study enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Impact of Implementation Strategies on LCS Shared Decision Making (SDM) completion
Prazo: up to 7 weeks after completion of LCS eligibility screen
|
Evaluate the impact of implementation strategies on Shared Decision Making (SDM) completion.
This outcome measure will report the proportion of patients who complete SDM.
|
up to 7 weeks after completion of LCS eligibility screen
|
|
Impact of Implementation Strategies on LCS Completion
Prazo: up to 6 months after placement of LCS referral
|
Evaluate the impact of implementation strategies on LCS completion.
This outcome measure will report the proportion of participants who complete LCS.
|
up to 6 months after placement of LCS referral
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Chelsey Schlechter, MPH, PhD, Huntsman Cancer Institute/ University of Utah
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 187448
- 1U48DP006855-01 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .